{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:08:32Z","timestamp":1782828512172,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008710","name":"Alzheimer's Australia Dementia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Health, State Government of Western Australia (AU)"},{"name":"Department of Health, State Government of Western Australia(AU)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s13346-017-0473-5","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T13:34:03Z","timestamp":1515418443000},"page":"543-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4\u00a0weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects"],"prefix":"10.1007","volume":"8","author":[{"given":"Armin","family":"Mooranian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Negrulj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Al-Sallami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0049-6969","authenticated-orcid":false,"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"issue":"1","key":"473_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jsams.2011.04.005","volume":"15","author":"MD Hordern","year":"2012","unstructured":"Hordern MD, Dunstan DW, Prins JB, Baker MK, Singh MA, Coombes JS. Exercise prescription for patients with type 2 diabetes and pre-diabetes: a position statement from Exercise and Sport Science Australia. J Sci Med Sport. 2012;15(1):25\u201331. \nhttps:\/\/doi.org\/10.1016\/j.jsams.2011.04.005\n\n.","journal-title":"J Sci Med Sport"},{"issue":"2","key":"473_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.atherosclerosis.2012.08.003","volume":"224","author":"JH Kwak","year":"2012","unstructured":"Kwak JH, Paik JK, Kim HI, Kim OY, Shin DY, Kim HJ, et al. Dietary treatment with rice containing resistant starch improves markers of endothelial function with reduction of postprandial blood glucose and oxidative stress in patients with prediabetes or newly diagnosed type 2 diabetes. Atherosclerosis. 2012;224(2):457\u201364. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.08.003\n\n.","journal-title":"Atherosclerosis"},{"issue":"4","key":"473_CR3","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.2337\/dc12-0997","volume":"36","author":"A Icks","year":"2013","unstructured":"Icks A, Claessen H, Strassburger K, Tepel M, Waldeyer R, Chernyak N, et al. Drug costs in prediabetes and undetected diabetes compared with diagnosed diabetes and normal glucose tolerance: results from the population-based KORA Survey in Germany. Diabetes Care. 2013;36(4):e53\u20134. \nhttps:\/\/doi.org\/10.2337\/dc12-0997\n\n.","journal-title":"Diabetes Care"},{"issue":"3","key":"473_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.diabres.2006.09.035","volume":"76","author":"SY Rhee","year":"2007","unstructured":"Rhee SY, Chon S, Oh S, Kim SW, Kim JW, Kim YS, et al. Insulin secretion and insulin resistance in newly diagnosed, drug naive prediabetes and type 2 diabetes patients with\/without metabolic syndrome. Diabetes Res Clin Pract. 2007;76(3):397\u2013403. \nhttps:\/\/doi.org\/10.1016\/j.diabres.2006.09.035\n\n.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"473_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ane.12474","volume":"133","author":"T Duksal","year":"2016","unstructured":"Duksal T, Tiftikcioglu BI, Bilgin S, Kose S, Zorlu Y. Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurol Scand. 2016;133(5):384\u201390. \nhttps:\/\/doi.org\/10.1111\/ane.12474\n\n.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"473_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1210\/en.2011-2183","volume":"153","author":"D Cai","year":"2012","unstructured":"Cai D. One step from prediabetes to diabetes: hypothalamic inflammation? Endocrinology. 2012;153(3):1010\u20133. \nhttps:\/\/doi.org\/10.1210\/en.2011-2183\n\n.","journal-title":"Endocrinology"},{"issue":"10","key":"473_CR7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.2337\/db11-0425","volume":"60","author":"F Karpe","year":"2011","unstructured":"Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011;60(10):2441\u20139. \nhttps:\/\/doi.org\/10.2337\/db11-0425\n\n.","journal-title":"Diabetes"},{"issue":"3","key":"473_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-0029-1211975","volume":"106","author":"C Karasu","year":"1998","unstructured":"Karasu C. Acute probucol treatment partially restores vasomotor activity and abnormal lipid metabolism whereas morphological changes are not affected in aorta from long-term STZ-diabetic rats. Exp Clin Endocrinol Diabetes. 1998;106(3):189\u201396. \nhttps:\/\/doi.org\/10.1055\/s-0029-1211975\n\n.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"473_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3109\/03639045.2011.637051","volume":"38","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S. Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improve in vitro dissolution and in vivo oral absorption. Drug Dev Ind Pharm. 2012;38(8):1015\u201323. \nhttps:\/\/doi.org\/10.3109\/03639045.2011.637051\n\n.","journal-title":"Drug Dev Ind Pharm"},{"key":"473_CR10","doi-asserted-by":"publisher","unstructured":"Al-Salami H, Mamo JC, Mooranian A, Negrulj R, Lam V, Elahy M, et al. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance. Exp Clin Endocrinol Diabetes. 2016; \nhttps:\/\/doi.org\/10.1055\/s-0042-106084\n\n.","DOI":"10.1055\/s-0042-106084"},{"issue":"7","key":"473_CR11","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3109\/21691401.2015.1069299","volume":"44","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif Cells Nanomed Biotechnol. 2016;44(7):1642\u201353. \nhttps:\/\/doi.org\/10.3109\/21691401.2015.1069299\n\n.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"6","key":"473_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3109\/02652048.2015.1065922","volume":"32","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Mikov M, Golocorbin-Kon S, Arfuso F, Al-Salami H. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study. J Microencapsul. 2015;32(6):589\u201397. \nhttps:\/\/doi.org\/10.3109\/02652048.2015.1065922\n\n.","journal-title":"J Microencapsul"},{"issue":"2","key":"473_CR13","first-page":"49","volume":"1","author":"R Negrulj","year":"2013","unstructured":"Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J Endocrinol Diab Mellitus. 2013;1(2):49\u201359.","journal-title":"J Endocrinol Diab Mellitus"},{"issue":"1","key":"473_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12249-014-0205-9","volume":"16","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech. 2015;16(1):45\u201352. \nhttps:\/\/doi.org\/10.1208\/s12249-014-0205-9\n\n.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"473_CR15","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3109\/21691401.2015.1024845","volume":"44","author":"R Negrulj","year":"2016","unstructured":"Negrulj R, Mooranian A, Chen-Tan N, Al-Sallami HS, Mikov M, Golocorbin-Kon S, et al. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 2016;44(5):1290\u20137. \nhttps:\/\/doi.org\/10.3109\/21691401.2015.1024845\n\n.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"10","key":"473_CR16","first-page":"17","volume":"27","author":"H Al-Salami","year":"2007","unstructured":"Al-Salami H, Kansara H, King J, Morar B, Jayathilaka B, Fawcett PJ, et al. Bile acids: a bitter sweet remedy for diabetes. N Z Pharm J. 2007;27(10):17\u201320.","journal-title":"N Z Pharm J"},{"key":"473_CR17","unstructured":"Mikov MA-SH, Golocorbin-Kon G. (2012) Potentials and limitations of bile acids and probiotics in diabetes mellitus. In pp 365\u2013402."},{"issue":"10","key":"473_CR18","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2337\/diabetes.32.10.900","volume":"32","author":"AB Thomson","year":"1983","unstructured":"Thomson AB. Uptake of bile acids into rat intestine. Effect of diabetes mellitus. Diabetes. 1983;32(10):900\u20137. \nhttps:\/\/doi.org\/10.2337\/diabetes.32.10.900\n\n.","journal-title":"Diabetes"},{"issue":"1","key":"473_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13346-015-0268-5","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable beta-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies. Drug Deliv Transl Res. 2016;6(1):17\u201323. \nhttps:\/\/doi.org\/10.1007\/s13346-015-0268-5\n\n.","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"473_CR20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s11095-016-1863-y","volume":"33","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. The influence of stabilized deconjugated ursodeoxycholic acid on polymer-hydrogel system of transplantable NIT-1 cells. Pharm Res. 2016;33(5):1182\u201390. \nhttps:\/\/doi.org\/10.1007\/s11095-016-1863-y\n\n.","journal-title":"Pharm Res"},{"issue":"2","key":"473_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12668-016-0198-9","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. Primary bile acid chenodeoxycholic acid-based microcapsules to examine \u03b2-cell survival and the inflammatory response. BioNanoSci. 2016;6(2):103\u20139. \nhttps:\/\/doi.org\/10.1007\/s12668-016-0198-9\n\n.","journal-title":"BioNanoSci"},{"key":"473_CR22","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2147\/DDDT.S68247","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther. 2014;8:1673\u201383. \nhttps:\/\/doi.org\/10.2147\/DDDT.S68247\n\n.","journal-title":"Drug Des Devel Ther"},{"key":"473_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DDDT.S67349","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur TK, et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther. 2014;8:1221\u201330. \nhttps:\/\/doi.org\/10.2147\/DDDT.S67349\n\n.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"473_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/02652048.2014.958204","volume":"32","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151\u20136. \nhttps:\/\/doi.org\/10.3109\/02652048.2014.958204\n\n.","journal-title":"J Microencapsul"},{"issue":"5","key":"473_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13346-015-0248-9","volume":"5","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Arfuso F, Al-Salami H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv and Transl Res. 2015;5(5):1\u201312. \nhttps:\/\/doi.org\/10.1007\/s13346-015-0248-9\n\n.","journal-title":"Drug Deliv and Transl Res"},{"issue":"1","key":"473_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF03191383","volume":"34","author":"H Al-Salami","year":"2009","unstructured":"Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2009;34(1):43\u201350. \nhttps:\/\/doi.org\/10.1007\/BF03191383\n\n.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"473_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1358\/mf.2008.30.2.1159652","volume":"30","author":"H Al-Salami","year":"2008","unstructured":"Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Methods Find Exp Clin Pharmacol. 2008;30(2):107\u201313. \nhttps:\/\/doi.org\/10.1358\/mf.2008.30.2.1159652\n\n.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"2","key":"473_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13318-011-0060-y","volume":"37","author":"H Al-Salami","year":"2012","unstructured":"Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2012;37(2):99\u2013108. \nhttps:\/\/doi.org\/10.1007\/s13318-011-0060-y\n\n.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"473_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11745-011-3595-4","volume":"47","author":"MM Pallebage-Gamarallage","year":"2012","unstructured":"Pallebage-Gamarallage MM, Galloway S, Takechi R, Dhaliwal S, Mamo JC. Probucol suppresses enterocytic accumulation of amyloid-\u03b2 induced by saturated fat and cholesterol feeding. Lipids. 2012;47(1):27\u201334. \nhttps:\/\/doi.org\/10.1007\/s11745-011-3595-4\n\n.","journal-title":"Lipids"},{"issue":"1","key":"473_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-11-117","volume":"11","author":"M Pallebage-Gamarallage","year":"2012","unstructured":"Pallebage-Gamarallage M, Lam V, Takechi R, Galloway S, Clark K, Mamo J. Restoration of dietary-fat induced blood\u2013brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids Health Dis. 2012;11(1):1.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"473_CR31","first-page":"532","volume":"60","author":"H Al-Salami","year":"2008","unstructured":"Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 2008;60(4):532\u201341.","journal-title":"Pharmacol Rep"},{"issue":"10","key":"473_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","volume":"18","author":"W Hempfling","year":"2003","unstructured":"Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid\u2014adverse effects and drug interactions. Aliment Pharmacol Ther. 2003;18(10):963\u201372. \nhttps:\/\/doi.org\/10.1046\/j.1365-2036.2003.01792.x\n\n.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"473_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbamcr.2006.04.014","volume":"1773","author":"A Geier","year":"2007","unstructured":"Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta. 2007;1773(3):283\u2013308. \nhttps:\/\/doi.org\/10.1016\/j.bbamcr.2006.04.014\n\n.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"473_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1161\/01.ATV.19.5.1325","volume":"19","author":"F Rinninger","year":"1999","unstructured":"Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999;19(5):1325\u201332. \nhttps:\/\/doi.org\/10.1161\/01.ATV.19.5.1325\n\n.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"473_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/mp500388m","volume":"12","author":"Q Ma","year":"2015","unstructured":"Ma Q, Han Y, Chen C, Cao Y, Wang S, Shen W, et al. Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes. Mol Pharm. 2015;12(3):665\u201374. \nhttps:\/\/doi.org\/10.1021\/mp500388m\n\n.","journal-title":"Mol Pharm"},{"issue":"5","key":"473_CR36","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1194\/jlr.M020743","volume":"53","author":"W Annema","year":"2012","unstructured":"Annema W, Dikkers A, de Boer JF, Gautier T, Rensen PC, Rader DJ, et al. ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. J Lipid Res. 2012;53(5):929\u201340. \nhttps:\/\/doi.org\/10.1194\/jlr.M020743\n\n.","journal-title":"J Lipid Res"},{"issue":"3","key":"473_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426\u201335. \nhttps:\/\/doi.org\/10.1007\/s00125-015-3844-9\n\n.","journal-title":"Diabetologia"},{"issue":"3","key":"473_CR38","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI68815","volume":"124","author":"F Lien","year":"2014","unstructured":"Lien F, Berthier A, Bouchaert E, Gheeraert C, Alexandre J, Porez G, et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest. 2014;124(3):1037\u201351. \nhttps:\/\/doi.org\/10.1172\/JCI68815\n\n.","journal-title":"J Clin Invest"},{"issue":"Pt 4","key":"473_CR39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/0004563212473450","volume":"50","author":"RP Vincent","year":"2013","unstructured":"Vincent RP, Omar S, Ghozlan S, Taylor DR, Cross G, Sherwood RA, et al. Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann Clin Biochem. 2013;50(Pt 4):360\u20134. \nhttps:\/\/doi.org\/10.1177\/0004563212473450\n\n.","journal-title":"Ann Clin Biochem"},{"issue":"10","key":"473_CR40","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.metabol.2007.06.009","volume":"56","author":"OD Carlson","year":"2007","unstructured":"Carlson OD, David JD, Schrieder JM, Muller DC, Jang H-J, Kim B-J, et al. Contribution of non-esterified fatty acids to insulin resistance in the elderly with normal fasting but diabetic 2h post challenge plasma glucose levels: Baltimore longitudinal study of aging. Metab Clin Exp. 2007;56(10):1444\u201351. \nhttps:\/\/doi.org\/10.1016\/j.metabol.2007.06.009\n\n.","journal-title":"Metab Clin Exp"},{"issue":"1","key":"473_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00019501-199401000-00009","volume":"5","author":"G Yoshino","year":"1994","unstructured":"Yoshino G, Matsushita M, Maeda E, Nagata K, Naka Y, Murata Y, et al. Effect of long-term administration of probucol on triglyceride turnover in rats. Coron Artery Dis. 1994;5(1):67\u201372. \nhttps:\/\/doi.org\/10.1097\/00019501-199401000-00009\n\n.","journal-title":"Coron Artery Dis"},{"issue":"1","key":"473_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1440-1681.12032","volume":"40","author":"R Takechi","year":"2013","unstructured":"Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Dhaliwal SS, Mamo JC. Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding. Clin Exp Pharmacol Physiol. 2013;40(1):45\u201352. \nhttps:\/\/doi.org\/10.1111\/1440-1681.12032\n\n.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"473_CR43","doi-asserted-by":"publisher","first-page":"138134","DOI":"10.1155\/2015\/138134","volume":"2015","author":"MI Saad","year":"2015","unstructured":"Saad MI, Kamel MA, Hanafi MY. Modulation of adipocytokines production and serum NEFA level by metformin, glimepiride, and sitagliptin in HFD\/STZ diabetic rats. Biochem Res Int. 2015;2015:138134\u20137. \nhttps:\/\/doi.org\/10.1155\/2015\/138134\n\n.","journal-title":"Biochem Res Int"},{"issue":"2","key":"473_CR44","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00125-011-2382-3","volume":"55","author":"C Beysen","year":"2012","unstructured":"Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012;55(2):432\u201342. \nhttps:\/\/doi.org\/10.1007\/s00125-011-2382-3\n\n.","journal-title":"Diabetologia"},{"issue":"1","key":"473_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1196\/annals.1372.039","volume":"1084","author":"K Alexandraki","year":"2006","unstructured":"Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Ann N Y Acad Sci. 2006;1084(1):89\u2013117. \nhttps:\/\/doi.org\/10.1196\/annals.1372.039\n\n.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"473_CR46","doi-asserted-by":"publisher","first-page":"7023","DOI":"10.4049\/jimmunol.166.12.7023","volume":"166","author":"U Christen","year":"2001","unstructured":"Christen U, Wolfe T, Mohrle U, Hughes AC, Rodrigo E, Green EA, et al. A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J Immunol. 2001;166(12):7023\u201332. \nhttps:\/\/doi.org\/10.4049\/jimmunol.166.12.7023\n\n.","journal-title":"J Immunol"},{"issue":"3","key":"473_CR47","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/jgh.12435","volume":"29","author":"SJ Koh","year":"2014","unstructured":"Koh SJ, Kim JM, Kim IK, Ko SH, Kim JS. Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. J Gastroenterol Hepatol. 2014;29(3):502\u201310. \nhttps:\/\/doi.org\/10.1111\/jgh.12435\n\n.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"473_CR48","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.2337\/db15-0090","volume":"64","author":"Y Hattori","year":"2015","unstructured":"Hattori Y, Hattori K, Hayashi T. Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms. Diabetes. 2015;64(6):1907\u20139. \nhttps:\/\/doi.org\/10.2337\/db15-0090\n\n.","journal-title":"Diabetes"},{"issue":"2","key":"473_CR49","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/btpr.2223","volume":"32","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H, Morahan G, Jamieson E. Designing anti-diabetic beta-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: morphology, bioenergetics, and cytokine analysis. Biotechnol Prog. 2016;32(2):501\u20139. \nhttps:\/\/doi.org\/10.1002\/btpr.2223\n\n.","journal-title":"Biotechnol Prog"},{"issue":"1","key":"473_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1471-230X-13-155","volume":"13","author":"H Buryova","year":"2013","unstructured":"Buryova H, Chalupsky K, Zbodakova O, Kanchev I, Jirouskova M, Gregor M, et al. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity. BMC Gastroenterol. 2013;13(1):155. \nhttps:\/\/doi.org\/10.1186\/1471-230X-13-155\n\n.","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"473_CR51","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1365-2982.2010.01510.x","volume":"22","author":"S Carotti","year":"2010","unstructured":"Carotti S, Guarino MP, Cicala M, Perrone G, Alloni R, Segreto F, et al. Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterol Motil. 2010;22(8):866\u2013873, e232. \nhttps:\/\/doi.org\/10.1111\/j.1365-2982.2010.01510.x\n\n.","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"473_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","volume":"129","author":"RM Onishi","year":"2010","unstructured":"Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311\u201321. \nhttps:\/\/doi.org\/10.1111\/j.1365-2567.2009.03240.x\n\n.","journal-title":"Immunology"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-017-0473-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-017-0473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-017-0473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T11:19:48Z","timestamp":1525432788000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-017-0473-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1007\/s13346-017-0473-5","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}